Featured Research

from universities, journals, and other organizations

Targeted Antiviral Prophylaxis Of Flu Case Contacts Could Successfully Contain Pandemic Influenza

Date:
March 2, 2004
Source:
Emory University Health Sciences Center
Summary:
In a future outbreak of pandemic influenza, such as the three pandemics that sickened millions and killed hundreds of thousands of people during the 20th century, supplies of flu vaccine might not be available quickly enough to contain the spread of disease.

ATLANTA – In a future outbreak of pandemic influenza, such as the three pandemics that sickened millions and killed hundreds of thousands of people during the 20th century, supplies of flu vaccine might not be available quickly enough to contain the spread of disease. However, according to research by biostatisticians in Emory University's Rollins School of Public Health, many thousands of deaths could be prevented if antiviral agents were given to the close contacts of those with suspected cases of flu until adequate supplies of vaccine could be manufactured and distributed. The results of the research by Emory professors of biostatistics Ira Longini, Jr,, PhD, and M. Elizabeth Halloran, MD, DSc, and their colleagues Azhar Nizam, MS, and Yang Yang, BSc, will appear online on March 26, and will be published as a special article in the American Journal of Epidemiology on April 1, 2004.

Related Articles


The Emory scientists used a dynamic stochastic simulation model of an influenza pandemic or bioterrorist attack for an agent similar to influenza A(H2N2), which caused the Asian influenza pandemic of 1957-58 and resulted in approximately 70,000 deaths in the U.S. (A stochastic model includes elements of chance or probability). They determined that if no interventions were used in a similar pandemic, 33 percent of the population would become ill, resulting in a death rate of 0.58 per 1,000 people. If antiviral prophylaxis was given to close contacts of 80% of suspected influenza cases, however, in a strategy that the authors call "targeted antiviral prophylaxis" (TAP), the epidemic could be contained. If TAP were begun within one day of identifying suspected flu cases and used for up to eight weeks, only 2 percent of the population would become ill, and the death rate would be only 0.04 per 1,000 people. The researchers found that eight weeks of TAP would be nearly as effective as vaccinating 80 percent of the population.

"The ability to rely on targeted antiviral therapy in the case of a major public health threat from influenza would be an extremely valuable strategy, due to the characteristics of influenza pandemics," Dr. Longini said. "Epidemics are usually due to strains of flu that acquire genetic variations that differ slightly from earlier strains, while pandemics occur when there is a dramatic shift in the current flu strain. Annual flu vaccines are designed to counter the strain of flu from the previous season, and often there is insufficient time to catch up with making enough vaccine to counter the first wave of a new outbreak. Manufacturing and distributing a vaccine to match a newly identified strain can take six to eight months."

Although the surveillance and containment strategy (i.e., isolation of cases and quarantine of close contacts) was recently used to successfully contain the spread of severe acute respiratory syndrome (SARS), influenza has a much shorter incubation period (1.9 days as opposed to 6.4 days), and has a much broader range of clinical illness, from asymptomatic to primary pneumonia. Thus the surveillance and containment strategy is unlikely to work in containing an influenza epidemic.

"Because surveillance and containment would be an ineffective strategy to contain an influenza epidemic, stockpiling antiviral drugs, along with a well-planned distribution strategy, could be an effective first line of defense while an adequate supply of vaccine is being produced to counter subsequent waves of infection," Dr. Longini explained.

Scientists already know that antiviral drugs can be used prophylactically to help prevent infection after exposure, to reduce the probability of clinical illness after infection, and to reduce the probability of transmission by infected individuals, as well as used therapeutically to reduce clinical illness and transmission after infection. The Emory model simulates what the population level effects would be for various TAP strategies. These include the indirect effects to people not directly receiving the intervention. The model population consisted of people whose characteristics simulated the age distribution and approximate household sizes from the U.S. 2000 Census. The spread of influenza was simulated through measuring typical numbers of close and casual contacts during the course of a day.

Although the researchers acknowledged that vaccination, if available, would be the most effective strategy to prevent an epidemic, they found that using TAP for up to four weeks would be almost as effective as vaccinating 50 percent of the entire population. TAP when used for up to eight weeks would be nearly as effective as vaccinating 80 percent of the entire population. If only limited quantities of vaccine were available, they found that vaccinating 80 percent of children younger than 19 would be nearly as effective as vaccinating 80 percent of the entire population.

"Although we know that vaccination is the best intervention for influenza, vaccine supplies may be limited," Dr. Halloran emphasized. "Using 80 percent TAP for six to eight weeks is almost as effective as vaccinating 80 percent of the entire population, but even given more limited supplies of antiviral agents, TAP for just one week could prevent millions of cases of influenza and save thousands of lives."

The researchers also addressed possible concerns about the emergence of drug-resistant influenza due to the widespread use of antivirals. Two classes of antiviral drugs– adamantanes and neuraminidase inhibitors – currently are used for influenza, either therapeutically or prophylactically. Drug resistance developing from prophylactic use of these agents has been shown to be much lower than for therapeutic use. The Emory scientists emphasize that the properties of neuraminidase inhibitors would lead to minimal spread of resistant strains with the TAP strategy, suggesting that this class of antiviral drug would be the best to stockpile for such use, followed by adamantanes.

"Effectiveness of the TAP strategy is based on systematic identification of index cases of influenza, and could be particularly effective in institutional settings such as schools, nursing homes and the workplace, and also for health care workers and first responders," Dr. Longini said. "If the logistical and financial details can be managed, the targeted use of antiviral drugs would be an effective first-line strategy for containing a pandemic influenza epidemic."


Story Source:

The above story is based on materials provided by Emory University Health Sciences Center. Note: Materials may be edited for content and length.


Cite This Page:

Emory University Health Sciences Center. "Targeted Antiviral Prophylaxis Of Flu Case Contacts Could Successfully Contain Pandemic Influenza." ScienceDaily. ScienceDaily, 2 March 2004. <www.sciencedaily.com/releases/2004/03/040302080210.htm>.
Emory University Health Sciences Center. (2004, March 2). Targeted Antiviral Prophylaxis Of Flu Case Contacts Could Successfully Contain Pandemic Influenza. ScienceDaily. Retrieved October 30, 2014 from www.sciencedaily.com/releases/2004/03/040302080210.htm
Emory University Health Sciences Center. "Targeted Antiviral Prophylaxis Of Flu Case Contacts Could Successfully Contain Pandemic Influenza." ScienceDaily. www.sciencedaily.com/releases/2004/03/040302080210.htm (accessed October 30, 2014).

Share This



More Health & Medicine News

Thursday, October 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Mind-Controlled Prosthetic Arm Restores Amputee Dexterity

Mind-Controlled Prosthetic Arm Restores Amputee Dexterity

Reuters - Innovations Video Online (Oct. 29, 2014) A Swedish amputee who became the first person to ever receive a brain controlled prosthetic arm is able to manipulate and handle delicate objects with an unprecedented level of dexterity. The device is connected directly to his bone, nerves and muscles, giving him the ability to control it with his thoughts. Matthew Stock reports. Video provided by Reuters
Powered by NewsLook.com
Google To Use Nanoparticles, Wearables To Detect Disease

Google To Use Nanoparticles, Wearables To Detect Disease

Newsy (Oct. 29, 2014) Google X wants to improve modern medicine with nanoparticles and a wearable device. It's all an attempt to tackle disease detection and prevention. Video provided by Newsy
Powered by NewsLook.com
Can Drinking Milk Lead To Early Death?

Can Drinking Milk Lead To Early Death?

Newsy (Oct. 29, 2014) Researchers in Sweden released a study showing heavy milk drinkers face an increased mortality risk from a variety of causes. Video provided by Newsy
Powered by NewsLook.com
Obama: The US Will Not 'run and Hide' From Ebola

Obama: The US Will Not 'run and Hide' From Ebola

AP (Oct. 29, 2014) Surrounded by health care workers in the White House East Room, President Barack Obama said the U.S. will likely see additional Ebola cases in the weeks ahead. But he said the nation can't seal itself off in the fight against the disease. (Oct. 29) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



    Save/Print:
    Share:

    Free Subscriptions


    Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

    Get Social & Mobile


    Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

    Have Feedback?


    Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
    Mobile: iPhone Android Web
    Follow: Facebook Twitter Google+
    Subscribe: RSS Feeds Email Newsletters
    Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins